Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK11 | Q15759 | 5/20 | 0.48 |
| ▸ | MAPK14 | Q16539 | 5/20 | 0.48 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.48 |
| ▸ | ACKR3 | P25106 | 1/20 | 0.47 |
| ▸ | GPR119 | Q8TDV5 | 2/20 | 0.44 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.42 |
| ▸ | JAK2 | O60674 | 1/20 | 0.40 |
| ▸ | JAK3 | P52333 | 1/20 | 0.40 |
| ▸ | PTK2 | Q05397 | 1/20 | 0.40 |
| ▸ | TP53 | P04637 | 1/20 | 0.40 |
| ▸ | MMP13 | P45452 | 1/20 | 0.39 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4763221 | 0.90 | MAPK11 (0.49) | MAPK11MAPK14KCNH2ACKR3ENPP2 | |
| SCHEMBL4721839 | 0.90 | MAPK11 (0.49) | MAPK11MAPK14KCNH2ACKR3ENPP2 | |
| SCHEMBL4761505 | 0.89 | MAPK11 (0.52) | MAPK11MAPK14KCNH2ACKR3ENPP2 | |
| SCHEMBL4722163 | 0.89 | MAPK11 (0.49) | MAPK11MAPK14KCNH2ACKR3ENPP2 | |
| SCHEMBL6004539 | 0.88 | MAPK11 (0.51) | MAPK11MAPK14KCNH2ACKR3 | |
| SCHEMBL6004476 | 0.87 | ACKR3 (0.41) | MAPK11MAPK14KCNH2ACKR3GPR119 | |
| SCHEMBL4762479 | 0.86 | MAPK11 (0.49) | MAPK11MAPK14KCNH2ACKR3ENPP2 | |
| SCHEMBL6004382 | 0.84 | MAPK11 (0.49) | MAPK11MAPK14KCNH2ACKR3 | |
| SCHEMBL4761409 | 0.84 | MAPK11 (0.52) | MAPK11MAPK14KCNH2ACKR3 | |
| SCHEMBL6003602 | 0.83 | MAPK11 (0.49) | MAPK11MAPK14KCNH2ACKR3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1871770-A1 | ORTHO-TERPHENYL INHIBITORS OF P38 KINASE AND METHODS OF TREATING INFLAMMATORY DISORDERS | Kalypsys, Inc. (US) | 2008-01-02 | — | — | EP | disclosed |
| US-20060252807-A1 | Novel ortho-terphenyl inhibitors of p38 kinase and methods of treating inflammatory disorders | KALYPSYS, INC. | 2006-11-09 | — | — | US | disclosed |
| WO-2006116355-A1 | ORTHO-TERPHENYL INHIBITORS OF P38 KINASE AND METHODS OF TREATING INFLAMMATORY DISORDERS | KALYPSYS, INC. (US) | 2006-11-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060252807-A1 | Novel ortho-terphenyl inhibitors of p38 kinase and methods of treating inflammatory disorders | MAPK1, MAP3K1, MAPK4 | MAPK11 45/4885MAPK14 26/4885KCNH2 4599/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.